Policy. OPV cessation--the final step to a "polio-free" world - PubMed (original) (raw)

. 2005 Oct 28;310(5748):625-6.

doi: 10.1126/science.1115547.

Affiliations

• PMID: 16254173
• DOI: 10.1126/science.1115547

Policy. OPV cessation--the final step to a "polio-free" world

R Bruce Aylward et al. Science. 2005.

Abstract

The 20-year, U.S. $4 billion-dollar international effort to eradicate wild polioviruses now includes monovalent oral poliovirus type 1 vaccine (mOPV1), which was first given to 40 million children in India in April 2005. As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis. This Policy Forum reviews the feasibility and implications of eventually stopping the use of live polio vaccines.

PubMed Disclaimer

Similar articles

• A vision of a world without polio: the OPV cessation strategy.
  Heymann DL, Sutter RW, Aylward RB. Heymann DL, et al. Biologicals. 2006 Jun;34(2):75-9. doi: 10.1016/j.biologicals.2006.03.005. Epub 2006 May 8. Biologicals. 2006. PMID: 16682224
• Risk management in a polio-free world.
  Bruce Aylward R, Sutter RW, Cochi SL, Thompson KM, Jafari H, Heymann D. Bruce Aylward R, et al. Risk Anal. 2006 Dec;26(6):1441-8. doi: 10.1111/j.1539-6924.2006.00840.x. Risk Anal. 2006. PMID: 17184391 Review.
• Progress toward interruption of wild poliovirus transmission--worldwide, January 2007-April 2008.
  Centers for Disease Control and Prevention (CDC). Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2008 May 9;57(18):489-94. MMWR Morb Mortal Wkly Rep. 2008. PMID: 18463607
• Role of genetic factors in polio eradication: new challenge for policy makers.
  Paul Y. Paul Y. Vaccine. 2007 Dec 5;25(50):8365-71. doi: 10.1016/j.vaccine.2007.09.068. Epub 2007 Oct 17. Vaccine. 2007. PMID: 17996995
• Polio eradication: the OPV paradox.
  Dowdle WR, De Gourville E, Kew OM, Pallansch MA, Wood DJ. Dowdle WR, et al. Rev Med Virol. 2003 Sep-Oct;13(5):277-91. doi: 10.1002/rmv.401. Rev Med Virol. 2003. PMID: 12931339 Review.

Cited by

• Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial.
  Snider CJ, Zaman K, Wilkinson AL, Binte Aziz A, Yunus M, Haque W, Jones KAV, Wei L, Estivariz CF, Konopka-Anstadt JL, Mainou BA, Patel JC, Lickness JS, Pallansch MA, Wassilak SGF, Steven Oberste M, Anand A. Snider CJ, et al. Vaccine. 2023 Sep 22;41(41):6083-6092. doi: 10.1016/j.vaccine.2023.08.055. Epub 2023 Aug 29. Vaccine. 2023. PMID: 37652822 Free PMC article. Clinical Trial.
• Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.
  Snider CJ, Zaman K, Estivariz CF, Yunus M, Weldon WC, Wannemuehler KA, Oberste MS, Pallansch MA, Wassilak SG, Bari TIA, Anand A. Snider CJ, et al. Lancet. 2019 Jun 29;393(10191):2624-2634. doi: 10.1016/S0140-6736(19)30503-3. Epub 2019 May 16. Lancet. 2019. PMID: 31104832 Free PMC article. Clinical Trial.
• The impact of supplementary immunization activities on routine vaccination coverage: An instrumental variable analysis in five low-income countries.
  Chakrabarti A, Grépin KA, Helleringer S. Chakrabarti A, et al. PLoS One. 2019 Feb 14;14(2):e0212049. doi: 10.1371/journal.pone.0212049. eCollection 2019. PLoS One. 2019. PMID: 30763389 Free PMC article.
• Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.
  Duintjer Tebbens RJ, Thompson KM. Duintjer Tebbens RJ, et al. BMC Infect Dis. 2015 Sep 24;15:390. doi: 10.1186/s12879-015-1114-6. BMC Infect Dis. 2015. PMID: 26404780 Free PMC article.
• Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
  Thompson KM, Duintjer Tebbens RJ. Thompson KM, et al. BMC Infect Dis. 2015 Sep 17;15:374. doi: 10.1186/s12879-015-1113-7. BMC Infect Dis. 2015. PMID: 26381878 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal